Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 5/20 | 0.60 |
| ▸ | MYC | P01106 | 5/20 | 0.51 |
| ▸ | CTSB | P07858 | 3/20 | 0.51 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.51 |
| ▸ | ELANE | P08246 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | NR4A1 | P22736 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28288439 | 0.86 | L3MBTL1 (0.50) | NOTUMMYCCTSBKLKB1ELANE | |
| SCHEMBL1259645 | 0.86 | MYC (0.50) | NOTUMMYCCTSBKLKB1ELANE | |
| SCHEMBL680769 | 0.85 | ALDH1A1 (0.57) | NOTUMMYCCTSBKLKB1ELANE | |
| SCHEMBL5757188 | 0.84 | NOTUM (0.60) | NOTUMMYCCTSBKLKB1ELANE | |
| SCHEMBL1260176 | 0.83 | MYC (0.55) | NOTUMMYCCTSBKLKB1ELANE | |
| SCHEMBL1259810 | 0.82 | MYC (0.57) | NOTUMMYCCTSBKLKB1ELANE | |
| SCHEMBL12892670 | 0.82 | MYC (0.47) | NOTUMMYCCTSBKLKB1ELANE | |
| SCHEMBL1259527 | 0.82 | NOTUM (0.66) | NOTUMMYCCTSBKLKB1ELANE | |
| SCHEMBL31554576 | 0.81 | MYC (0.50) | NOTUMMYCCTSBKLKB1ELANE | |
| SCHEMBL1259756 | 0.81 | NOTUM (0.50) | NOTUMMYCCTSBKLKB1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371428-B2 | Pyridone compounds and methods of use | EXELIXIS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| WO-2025096463-A1 | PLK4 MODULATORS | VIBLIOME THERAPEUTICS, LLC (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-4340839-B1 | NOVEL AZAINDOLE DERIVATIVES AS ANTIVIRAL AGENTS | CENTRE NAT RECH SCIENT (FR) | 2025-02-12 | — | — | EP | disclosed |
| WO-2024251182-A1 | QUINOXALINE COMPOUND AND USE THEREOF | 广州六顺生物科技有限公司 | 2024-12-12 | — | — | WO | disclosed |
| CN-119101036-A | Quinoxaline compound and application thereof | 广州六顺生物科技有限公司 | 2024-12-10 | — | — | CN | disclosed |
| US-20240293386-A1 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR | LG CHEM, LTD. (KR) | 2024-09-05 | — | — | US | disclosed |
| US-20240293400-A1 | NOVEL AZAINDOLE DERIVATIVES AS ANTIVIRAL AGENTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2024-09-05 | — | — | US | disclosed |
| US-20240239795-A1 | NOVEL AZAINDOLE DERIVATIVES AS ANTIVIRAL AGENTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2024-07-18 | — | — | US | disclosed |
| US-20240174666-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC. (US) | 2024-05-30 | — | — | US | disclosed |
| EP-3762392-B1 | THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | WELLMARKER BIO CO LTD (KR) | 2024-05-15 | — | — | EP | disclosed |
| US-7439246-B2 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-21 | — | — | US | disclosed |
| CN-101005843-A | Pyrrolotriazine kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2007-07-25 | — | — | CN | disclosed |
| EP-1761268-A2 | PYRROLOTRIAZINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-03-14 | — | — | EP | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-21 | — | — | US | disclosed |
| WO-2006004833-A2 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-01-12 | — | — | WO | disclosed |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-05 | — | — | US | disclosed |
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | NOTUM 2559/4885MYC 493/4885CTSB 3604/4885 |
| US-12371428-B2 | Pyridone compounds and methods of use | PDXK, PLK2, MAP4K2 | NOTUM 2932/4885MYC 2168/4885CTSB 3997/4885 |
| US-20240293400-A1 | NOVEL AZAINDOLE DERIVATIVES AS ANTIVIRAL AGENTS | AXL, ZC3HAV1, MERTK | NOTUM 3445/4885MYC 2539/4885CTSB 1438/4885 |
| US-20240239795-A1 | NOVEL AZAINDOLE DERIVATIVES AS ANTIVIRAL AGENTS | AXL, ABL1, ZC3HAV1 | NOTUM 3517/4885MYC 2256/4885CTSB 1316/4885 |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | MAP3K5, MAP3K15, MAP4K2 | NOTUM 2274/4885MYC 1334/4885CTSB 2861/4885 |
| US-20240174666-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | RET, MERTK, MET | NOTUM 4687/4885MYC 594/4885CTSB 1794/4885 |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | NOTUM 2559/4885MYC 493/4885CTSB 3604/4885 |
| US-20240293386-A1 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR | MAP3K20, SBK3, MAPKAPK2 | NOTUM 1923/4885MYC 430/4885CTSB 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.